TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells - PubMed (original) (raw)

. 2015 Feb 5;34(6):681-90.

doi: 10.1038/onc.2014.5. Epub 2014 Feb 17.

R Dattilo 1, C Moriconi 1, A Pagliuca 1, M Mottolese 2, G Federici 2, A Di Benedetto 2, M Todaro 3, G Stassi 3, F Sperati 2, M I Amabile 4, E Pilozzi 5, M Patrizii 1, M Biffoni 1, M Maugeri-Saccà 2, S Piccolo 6, R De Maria 2

Affiliations

TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells

M Bartucci et al. Oncogene. 2015.

Abstract

Metastatic growth in breast cancer (BC) has been proposed as an exclusive property of cancer stem cells (CSCs). However, formal proof of their identity as cells of origin of recurrences at distant sites and the molecular events that may contribute to tumor cell dissemination and metastasis development are yet to be elucidated. In this study, we analyzed a set of patient-derived breast cancer stem cell (BCSC) lines. We found that in vitro BCSCs exhibit a higher chemoresistance and migratory potential when compared with differentiated, nontumorigenic, breast cancer cells (dBCCs). By developing an in vivo metastatic model simulating the disease of patients with early BC, we observed that BCSCs is the only cell population endowed with metastatic potential. Gene-expression profile studies comparing metastagenic and non-metastagenic cells identified TAZ, a transducer of the Hippo pathway and biomechanical cues, as a central mediator of BCSCs metastatic ability involved in their chemoresistance and tumorigenic potential. Overexpression of TAZ in low-expressing dBCCs induced cell transformation and conferred tumorigenicity and migratory activity. Conversely, loss of TAZ in BCSCs severely impaired metastatic colonization and chemoresistance. In clinical data from 99 BC patients, high expression levels of TAZ were associated with shorter disease-free survival in multivariate analysis, thus indicating that TAZ may represent a novel independent negative prognostic factor. Overall, this study designates TAZ as a novel biomarker and a possible therapeutic target for BC.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Clin Cancer Res. 2011 Aug 1;17(15):4942-7 - PubMed
    1. Cell. 2008 May 16;133(4):704-15 - PubMed
    1. J Clin Oncol. 2008 Feb 10;26(5):729-35 - PubMed
    1. Cell. 2011 Nov 11;147(4):759-72 - PubMed
    1. Br J Cancer. 2013 Jun 25;108(12):2525-36 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources